Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7898444 | 0.90 | GRM5 (0.54) | GRM5SMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL7907942 | 0.81 | HSD11B1 (0.45) | GRM5 | |
| SCHEMBL7910110 | 0.81 | GRM5 (0.72) | GRM5SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL3101805 | 0.81 | SMN1; SMN2 (0.52) | SMN1; SMN2RAB9ANPC1ALDH1A1LMNA | |
| SCHEMBL7904713 | 0.81 | TMPRSS4 (0.55) | GRM5CYP1A2CYP2C9 | |
| SCHEMBL3860067 | 0.80 | GRM5 (1.00) | GRM5SMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL1795107 | 0.80 | GRM5 (0.70) | GRM5SMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL7909702 | 0.80 | RAB9A (0.51) | GRM5SMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL7913781 | 0.80 | ALDH1A1 (0.52) | SMN1; SMN2RAB9ANPC1ALDH1A1LMNA | |
| SCHEMBL3788701 | 0.79 | RXFP1 (0.49) | SMN1; SMN2RAB9ANPC1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010100050-A1 | PYRIDINE-2-YL-CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-20100227887-A1 | PYRIDINE-2-YL CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227887-A1 | PYRIDINE-2-YL CARBOXYLIC ACID AMIDES | GRM2, GRM1, GRM3 | GRM5 6/4885SMN1; SMN2 2966/4885RAB9A 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.